Abstract
Background:
The placement of Spinal Cord Stimulator (SCS) trial or permanent electrodes carries a 31.9-43% morbidity/adverse event (AE) rate. Most AEs are attributed to electrode migration (EM: device-related AE 26.7% older cohort vs. 9.7% newer cohort), spinal epidural hematomas (SEHs: 0.81-2.6%), infection (3.4% older vs. 1.9% recent cohort), SCI (spinal cord injury: percutaneous 0.45% vs. 0.36% paddle electrodes), dural tears (DT/ cerebrospinal fluid leaks (CSF leaks)), foreign body/fibrous reactions, or syrinx formation.
Methods:
SCSs are typically applied to address chronic neuropathic pain syndromes. Here, we evaluated 20 articles focusing on patients who developed postoperative myelopathy/radiculopathy, variously attributed to MR-documented AE warranting medical or surgical intervention.
Results:
Postoperative symptoms/signs of AE typically included the acute development of new/increased weakness, sensory loss, and/or sphincter dysfunction. Requisite STAT MR scans usually confirmed the etiology of AE including electrode migration, SEH, DT, SCI, and/or postoperative scarring/fibrosis. Most patients warranted STAT surgery, while a small subset could be managed conservatively.
Conclusion:
The AE rate for spinal cord stimulators ranges from 31.9 to 43%. While the majority are due to electrode migration, other etiologies include SEH, SCI, DT, and foreign body reactions. Those who become acutely myelopathic usually warrant STAT MR scans with the majority additionally necessitating STAT surgical intervention to limit short/long-term neurological morbidity.
Keywords: Spinal Epidural Hematomas (SEHs), Spinal Cord Stimulator (SCS), Trials, Permanent Electrodes, STAT MR Scans, STAT Decompressive Surgery
INTRODUCTION
The placement of spinal cord stimulator (SCS) trial or permanent electrodes carries a 31.9-43% risk of morbidity/adverse event (AE) [Table 1]. While AEs are largely attributed to electrode migration (EM), other factors include spinal epidural hematomas (SEHs: 0.81% to 2.6%), infection, spinal cord injury (SCI: percutaneous electrodes 0.45% vs. 0.36% for paddle electrodes), dural tears (DT), foreign body/fibrous reactions, or syrinx formation. Our review of 20 articles focused on the postoperative onset of new/increased myelopathy/radiculopathy deficits variously attributed to MR-documented postoperative AE. Although most cases warrant surgical intervention, there is a small subset that can be managed conservatively.
Table 1:
Summary of morbidity of spinal cord stimulator (SCS) trials and implants.

What are the Adverse Events (AE) Associated with SCS?
Several studies asked whether SCS, including trial or permanent electrode placement, is safe [Table 1]?[1,2,5,10,11,16,18] Bendersky et al. (2014) observed that most reoperations address electrode migration with/without repositioning, followed by spinal epidural hematomas (SEHs), spinal cord injury (SCI), infection, dural tears (DTs), foreign body reactions/fibrosis, and postoperative pain.[2] Taccola et al. (2020) discussed multiple adverse events following the placement of SCS that included most often electrode migration, localized foreign body reactions/fibrosis and encapsulation that could surround the SCS electrodes, and glial/collagenous changes.[18] Jenkinson et al. (2022) also found electrode migration to be the most frequent AE with SCS placement in 35 patients undergoing the application of 69 leads; patients sustained an average of 28 mm of 1.17 levels of migration, more frequently occurring during SCS electrode trial placements.[10] In 2023, Garg et al. estimated an overall 31.9-43% risk for SCS largely addressing the same risk factors and followed up with the recommendation for close postoperative observation and early diagnosis and treatment when AE occurred.[5]Koushik et al. (2024) similarly cited electrode migration/ fractures, SCI, SEH, infection, dural tear, and skin erosion over SCS-implanted devices while also noting that many required additional surgical intervention.[11] Further, Song et al. (2024) determined in a series of 27 patients that postoperative electrode lead migration typically occurred within 1-2 postoperative days.[16] Utilizing dynamic films, they demonstrated an average of 18.2 mm of cephalad and 19.1 mm of caudal migration, with 20/27 (74%) patients developing clinically significant symptoms that correlated with these findings.
Incidence of Spinal Epidural Hematomas (SEHs) Following SCS Placement
Two Large Series
Two large studies documented that the incidence of neuroaxis-related SEH attributed to SCS placement ranged from 0.32 to 2.6% vs. lower 0.59% to 0.8% rates of postoperative thoracic hematomas observed without the application of SCS [Table 1].[13,20] Moufarrij et al. (2016) compared the frequency of postoperative SEH for 154 patients undergoing thoracic paddle SCS placement (2002-2015) vs. those having thoracic laminectomies alone (119); they found a 2.6% incidence (4/154) of SEH for SCS vs. 1/119 (0.8%) without SCS.[13] Here, the authors concluded that SEH likely occurred due to direct trauma to the epidural venous plexus (i.e., a higher rate of hemorrhages attributed to placing paddle electrodes). In 2023, West et al. 40-study meta-analysis compared the incidence of postoperative neuraxial SEH following SCS placement (SEH 4751 cases) vs. nonneuraxial hematomas (3862); 0.32% developed neuraxial SEH (11/4751) vs. 0.59% for nonneuraxial hematomas.[20]
Two Case Studies of SEH Following SCS Placement
Following SCS placement, 2 patients developed new postoperative myelopathy attributed to MR-documented acute SEH [Table 1].[6,9] Jaffee et al. (2025) 43-year-old male, who had received appropriate von Willebrand’s disease prophylaxis 7 days before the SCS, presented 1 month later with new myelopathy attributed to an MR-confirmed SEH; once the clot was removed, the patient’s deficit resolved over a 6-month period.[9] In 2026, Giakas et al. reported that a patient in his forties underwent placement of an SCS trial. The immediate onset of postoperative severe myelopathy prompted obtaining a STAT MR that documented a C6-L2 SEH (maximal T10/T11 to L2); following clot removal, the patient rapidly recovered.[6] Interestingly, the patient’s history of pulmonary hypertension likely contributed to significant epidural venous congestion that probably predisposed him to the SEH.
Mixed Results for Continuing or Stopping Anti-Platelet Therapy Before SCS Placement
One case report and a larger series offered conflicting recommendations as to whether to continue vs. discontinue antiplatelet agents before performing SCS to avert postoperative hemorrhages [Table 1].[3,12] Buvanendran et al. (2014) 73 year-old female underwent a percutaneous SCS lead placement while continuing aspirin (81 mg/day); within 24 postoperative hours, the STAT MR diagnosed a symptomatic SEH that required emergent removal. Here, the authors concluded “Prior to interventional pain procedures, one should contemplate cessation of aspirin therapy because there are, at present, no consensus guidelines to direct such a decision.”[3] In a subsequent large series in 2016, Moeschler et al. evaluated the incidence of postoperative hemorrhages (i.e. including SEH) for placing 642 SCS in 421 patients (i.e., percutaneous (346 cases) or trial electrodes (255 cases), or revision procedures (41 cases)).[12] Here, guidelines were interpreted as not including the cessation of ASA or NSAIDS 7 days before SCS procedures in 101 patients (15.7%); interestingly, none sustained bleeds and/or SEH. Here, the authors opined “Future investigations with larger numbers are needed to better define the relationships between periprocedural aspirin and NSAID utilization and bleeding complications.” In short, no consensus is provided by the literature regarding whether to stop ASA/NSAIDS before SCS placement, but many spinal surgeons would and should likely stop these medications before spine surgery out of an abundance of caution.
Three Studies Discussed Spinal Cord Injury (SCI) Following SCS Placement
Three studies discussed the potential for SCI following SCS placement [Table 1].[4,8,15] In 2011, Cai et al. in general discussed the rarity of SCI following SCS placement and attributed many of these to postprocedural spinal epidural hematomas (SEHs) often requiring emergent evacuation.[4] Smith et al. (2010) presented 4 cases of SCI occurring after SCS trial/implant placement.[15] These resulted in one intramedullary cord contusion (i.e., due to cord penetration with the needle), and 3 cases of epidural spinal cord compression (i.e. in 2 cases due to SEH, and one from a thoracic disc herniation). Following SCS removal, patients postoperatively were paraplegic (1 case), paretic (2 cases), or regained full function (1 case). In a large database, Hussain et al. (2022) found that the incidence of SCI following the placement of SCS percutaneous electrodes was 0.45% (233/52,070) vs. 0.36% for paddle electrodes (69/19,102).[8] Of note, the risk for SCI increased for patients undergoing SCS while still on subcutaneous low-molecular-weight heparin prophylaxis and those with underlying cervical or thoracic stenosis.
Case of Fibrotic Epidural Mass Causing CES 17 Years Following SCS
In 2025, Wackerly et al. had a 48-year-old female who presented 17 years following the placement of an SCS with a Brown–Sequard syndrome (i.e., ipsilateral paraparesis, a contralateral T10 sensory level, and bowel incontinence) [Table 1].[19] As the MR documented spinal epidural cord compression at the T9/T10 level, she underwent removal of what proved to be an epidural fibrotic mass. Within 4 postoperative weeks, she was asymptomatic.
Rare Case of Spinal Cord Infarct Immediately Following SCS Placement
Ramkumar et al. (2025) described a 76-year-old female who developed a spinal cord infarct and immediate postoperative bilateral paraplegia following placement of an SCS [Table 1].[14] The MR documented a spinal cord infarct extending from the C7-L2 levels. Interestingly, she was managed conservatively (i.e., without surgery) and showed partial recovery of left leg function, but persistent right leg paresis.
If SCS Placement Results in a Dural Tear, How Often is the Procedure Continued at That Level, Another Level, Discontinued, or an Alternative Option Taken?
In 2022, using data from 2 societies (i.e., SIS=Spine Intervention Society, ASRA=American Society of Regional Anesthesia), Southerland et al. (2022) evaluated how often surgeons continued to operate at the same level, at another level, discontinued the procedure, or chose another approach when dural tears occurred during SCS placement [Table 1].[17] If DT occurred placing a trial vs. permanent electrode, surgeons continued to perform the procedure at the same level (10.4% vs. 10.6%), chose to operate at another level (56.9% vs. 61.7%), aborted the procedure (27.8% vs. 21.7%), or chose an alternative operative approach entirely 4.6% vs. 6.1%).
Decreased Morbidity for More Recently Performed SCS Procedures 2016-2021 vs. Older Procedures Completed From 1999-2015
Ho et al. (2024) compared the frequency of adverse events occurring following SCS placement in patients operated on more recently between 2016 and 2021 and compared these AE with those from patients previously undergoing surgery from 1999 to 2015 [Table 1].[7] Patients undergoing surgery 2016-2021 averaged 58.5 years of age and their overall AE rate was 14% vs. an average age of 50.6 for those having surgery from 1999 to 2015 whose overall AE rate was 38.9%. More specifically, those recently operated on exhibited a lower infection rate vs. the older cohort (1.9% vs. 3.4%) and a decreased incidence of device-related AE (9.7% vs. 26.7%).
CONCLUSION
The AE rate for spinal cord stimulators ranges from 31.9% to 43% [Table 1]. Most AEs are attributed to electrode migration (EM: device-related AE 26.7% older cohort vs. 9.7% newer cohort), spinal epidural hematomas (SEHs: 0.81-2.6%), infection (3.4% older vs. 1.9% recent cohort), SCI (spinal cord injury: percutaneous 0.45% vs. 0.36% paddle electrodes), dural tears (DT/cerebrospinal fluid leaks (CSF leaks)), foreign body/fibrous reactions, or syrinx formation.
Footnotes
How to cite this article: Epstein NE, Agulnick MA. Perspective/ short review: Adverse events associated with placement of spinal cord stimulators. Surg Neurol Int. 2026;17:258. doi: 10.25259/SNI_405_2026
Contributor Information
Nancy E. Epstein, Email: nancy.epsteinmd@gmail.com.
Marc A. Agulnick, Email: agulnick@yahoo.com.
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
Patient’s consent is not required as there are no patients in this study.
Financial support and sponsorship:
Nil.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Disclaimer
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.
REFERENCES
- 1.Baur A, Lustig K. Spinal epidural hematoma and permanent paraplegia following spinal cord stimulator implantation: A case report. J Spine Surg. 2024;10:576–82. doi: 10.21037/jss-23-139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bendersky D, Yampolsky C. Is spinal cord stimulation safe? A review of its complications. World Neurosurg. 2014;82:1359–68. doi: 10.1016/j.wneu.2013.06.012. [DOI] [PubMed] [Google Scholar]
- 3.Buvanendran A, Young AC. Spinal epidural hematoma after spinal cord stimulator trial lead placement in a patient taking aspirin. Reg Anesth Pain Med. 2014;39:70–2. doi: 10.1097/AAP.0000000000000029. [DOI] [PubMed] [Google Scholar]
- 4.Cai HX, Liu C, Zhang JF, Wan SL, Uchida K, Fan SW. Spontaneous epidural hematoma of thoracic spine presenting as brown-séquard syndrome: Report of a case with review of the literature. J Spinal Cord Med. 2011;34:432–6. doi: 10.1179/107902611X13069205199468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Garg I, Wang D. Complications of spinal cord stimulator trials and implants: A review. Curr Pain Headache Rep. 2023;27:837–42. doi: 10.1007/s11916-023-01190-7. [DOI] [PubMed] [Google Scholar]
- 6.Giakas AM, Milano ME, Gehret JA, Rihn JA. Compressive cervicothoracolumbar epidural haematoma following lead insertion for spinal cord stimulator trial. BMJ Case Rep. 2026;19:e268333. doi: 10.1136/bcr-2025-268333. [DOI] [PubMed] [Google Scholar]
- 7.Ho JS, Glicksman M, Kang K, Zhang EX, Phung AT, Therond A, et al. Spinal Cord stimulator complication rates: A single-institution, 22-year study (1999-2021) Pain Physician. 2024;27:E909–17. [PubMed] [Google Scholar]
- 8.Hussain N, Gill J, Speer J, Abdel-Rasoul M, Abd-Elsayed A, Khan S, et al. Evaluating the incidence of spinal cord injury after spinal cord stimulator implant: An updated retrospective review. Reg Anesth Pain Med. 2022;47:401–7. doi: 10.1136/rapm-2021-103307. [DOI] [PubMed] [Google Scholar]
- 9.Jaffee S, Mamadhi J, Kite T, Kramer DE, Tomycz N. Delayed epidural hematoma after spinal cord stimulator implantation in a patient with von Willebrand disease: Illustration. Surg Neurol Int. 2025;16:227. doi: 10.25259/SNI_311_2025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Jenkinson RH, Wendahl A, Zhang Y, Sindt JE. Migration of epidural leads during spinal cord stimulator trials. J Pain Res. 2022;15:2999–3005. doi: 10.2147/JPR.S378937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Koushik SS, Raghavan J, Saranathan S, Slinchenkova K, Viswanath O, Shaparin N. Complications of spinal cord stimulators-a comprehensive review article. Curr Pain Headache Rep. 2024;28:1–9. doi: 10.1007/s11916-023-01178-3. [DOI] [PubMed] [Google Scholar]
- 12.Moeschler SM, Warner NS, Lamer TJ, Bendel MA, Warner MA, Eldrige JS, et al. Bleeding complications in patients undergoing percutaneous spinal cord stimulator trials and implantations. Pain Med. 2016;17:2076–81. doi: 10.1093/pm/pnw124. [DOI] [PubMed] [Google Scholar]
- 13.Moufarrij NA. Epidural hematomas after the implantation of thoracic paddle spinal cord stimulators. J Neurosurg. 2016;125:982–5. doi: 10.3171/2015.8.JNS15396. [DOI] [PubMed] [Google Scholar]
- 14.Ramkumar V, Maljaars J. Spinal cord infarction as an immediate complication of spinal cord stimulator placement. Pain Med Case Rep. 2025;9:349–52. [PubMed] [Google Scholar]
- 15.Smith CC, Lin JL, Shokat M, Dosanjh SS, Casthely D. A report of paraparesis following spinal cord stimulator trial, implantation and revision. Pain Physician. 2010;13:357–63. [PubMed] [Google Scholar]
- 16.Song WH, Jen TT, Osborn JA, Varshney V. Early epidural lead migration in spinal cord stimulator trials: A case series. Interv Pain Med. 2024;3:100426. doi: 10.1016/j.inpm.2024.100426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Southerland WA, Hasoon J, Urits I, Viswanath O, Simopoulos TT, Imani F, et al. Dural puncture during spinal cord stimulator lead insertion: Analysis of practice patterns. Anesth Pain Med. 2022;12:e127179. doi: 10.5812/aapm-127179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Taccola G, Barber S, Horner PJ, Bazo HA, Sayenko D. Complications of epidural spinal stimulation: Lessons from the past and alternatives for the future. Spinal Cord. 2020;58:1049–59. doi: 10.1038/s41393-020-0505-8. [DOI] [PubMed] [Google Scholar]
- 19.Wackerly R, Castano V, Wang VY. Sudden onset Brown-Sequard-like symptoms due to fibrotic scar tissue formation around spinal cord stimulator electrode with associated spinal cord compression. Surg Neurol Int. 2025;16:493. doi: 10.25259/SNI_1077_2025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.West T, Driver CN, D’Souza RS. Incidence of neuraxial and non-neuraxial hematoma complications from spinal cord stimulator surgery: Systematic review and proportional meta-analysis. Neuromodulation. 2023;26:1328–38. doi: 10.1016/j.neurom.2022.07.005. [DOI] [PubMed] [Google Scholar]
